CRTX.L

CRISM Therapeutics Corporation
Crism Therapeutics - Director Dealing
3rd June 2024, 14:25
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 9176Q
Crism Therapeutics Corporation
03 June 2024
 

3 June 2024

 

CRISM Therapeutics Corporation

(AIM:CRTX)

 

Director Dealing

 

CRISM Therapeutics Corporation ("CRISM" or the "Company") announces that it has been notified that Non-Executive Director, Gerald Beaney has purchased 25,000 ordinary shares of the Company at a price of 9.265 pence per share.

 

Following this purchase, Mr Beaney holds 25,000 ordinary shares, which represents approximately 0.08% of the Company's total issued share capital of 32,678,312.

 

 

Enquiries:

 

Company

Nomad and Broker

Financial PR

CRISM Therapeutics Corporation

S.P. Angel Corporate Finance LLP

Buchanan

Andrew Webb, CEO

Chris McConville, CSO

Richard Morrison

Adam Cowl

 

Mark Court mark.court@buchanancomms.co.uk

Jamie Hooper jamie.hooper@buchanancomms.co.uk

via Buchanan

+44 (0) 20 3470 0470

+44 (0) 20 7466 5000

 

 

 

Dealings by Persons Discharging Managerial Responsibilities

 

 1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Gerald Beaney

2

 

Reason for the notification

 

a)

 

Position/status

Non-Executive Director

b)

 

Initial notification /Amendment

 Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 CRISM Therapeutics Corporation

b)

 

LEI

 

213800XFW6MKVCHHPW88

 

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary shares with no par value



Identification code

ISIN: VGG042401262

 



b)

 

Nature of the transaction

 

Purchase of shares

c)

 

Price(s) and volume(s)

 

 

 

 

Director/PDMR

Price

Volume

Gerald Beaney

9.265

25,000

 

 

 

 

 

 

 

 

 

 

 

d)

 

Aggregated information




- Aggregated volume

 25,000



- Price

£2,316.25



e)

 

Date of the transaction

3 June 2024

f)

 

Place of the transaction

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFFSRSIVIIS]]>
TwitterFacebookLinkedIn